~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epil
Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.